The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.

Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets realistic, patient-specific goals around activity control and repigmentation.

Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

Oncology leaders say clinical pathways must shift from static documents to tools that use patient-reported outcomes and AI to guide care.

SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure ...

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.

First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.

The University of Exeter’s David Halpin, MA, DPhil, explains why GOLD 2026 treats a single COPD exacerbation as a trigger to ...